AH
MYGN icon

Andreas Halvorsen’s Myriad Genetics MYGN Stock Holding History

Andreas Halvorsen’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,330,294
Closed -$51.8M – 71
2014
Q2 		$51.8M Buy
+1,330,294
New +$49.5M 0.23% 54

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 16.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Andreas Halvorsen's MYGN Position: Q3 2014 in Review

Andreas Halvorsen sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 1,330,294 shares — an estimated $51.8M sold.

Andreas Halvorsen first reported a position in MYGN in Q2 2014 and held it in 1 quarter. The position peaked at $51.8M in Q2 2014. 276 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • Andreas Halvorsen reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
  • Andreas Halvorsen sold 1,330,294 Myriad Genetics shares in Q3 2014, an estimated $51.8M.
  • Andreas Halvorsen first reported a position in Myriad Genetics in Q2 2014 and held it in 1 quarter.
  • Andreas Halvorsen's Myriad Genetics position peaked at $51.8M in Q2 2014.
  • 276 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on Viking Global Investors's 13F filing for Q3 2014, filed 14 Nov 2014.